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Abstract
The tumour suppressor p53, encoded by TP53, is a key player in a wide network of signalling 
pathways. We investigated its role in the bioactivation of the environmental carcinogen 
3-nitrobenzanthrone (3-NBA)found in diesel exhaust and its metabolites 3-aminobenzanthrone 
(3-ABA) and N-hydroxy-3-aminobenzanthrone (N-OH-3-ABA) in a panel of isogenic human 
colorectal HCT116 cells differing only with respect to their TP53 status [i.e. TP53(+/+), TP53(+/−), 
TP53(−/−), TP53(R248W/+) or TP53(R248W/−)]. As a measure of metabolic competence, DNA 
adduct formation was determined using 32P-postlabelling. Wild-type (WT) p53 did not affect 
the bioactivation of 3-NBA; no difference in DNA adduct formation was observed in TP53(+/+), 
TP53(+/−) and TP53(−/−) cells. Bioactivation of both metabolites 3-ABA and N-OH-3-ABA on the 
other hand was WT-TP53 dependent. Lower 3-ABA- and N-OH-3-ABA-DNA adduct levels were 
found in TP53(+/−) and TP53(−/−) cells compared to TP53(+/+) cells, and p53’s impact was attributed 
to differences in cytochrome P450 (CYP) 1A1 expression for 3-ABA whereas for N-OH-3-ABA, an 
impact of this tumour suppressor on sulphotransferase (SULT) 1A1/3 expression was detected. 
Mutant R248W-p53 protein function was similar to or exceeded the ability of WT-p53 in activating 
3-NBA and its metabolites, measured as DNA adducts. However, identiﬁcation of the xenobiotic-
metabolising enzyme(s) (XMEs), through which mutant-p53 regulates these responses, proved 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),  
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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difﬁcult to decipher. For example, although both mutant cell lines exhibited higher CYP1A1 
induction after 3-NBA treatment compared to TP53(+/+) cells, 3-NBA-derived DNA adduct levels 
were only higher in TP53(R248W/−) cells but not in TP53(R248W/+) cells. Our results show that 
p53’s inﬂuence on carcinogen activation depends on the agent studied and thereby on the XMEs 
that mediate the bioactivation of that particular compound. The phenomenon of p53 regulating 
CYP1A1 expression in human cells is consistent with other recent ﬁndings; however, this is the 
ﬁrst study highlighting the impact of p53 on sulphotransferase-mediated (i.e. SULT1A1) carcinogen 
metabolism in human cells.
Introduction
Combustion-derived pollutants are released into the environment 
from industrial activities, traf"c emissions and domestic heating. 
Outdoor air pollution and diesel engine exhaust have been classi"ed 
as carcinogenic to humans (Group 1) by the International Agency 
for Research on Cancer (IARC) and are both linked to other respira-
tory diseases besides lung cancer, such as allergic asthma and chronic 
obstructive pulmonary disease  (1,2). The mechanisms involved in 
lung carcinogenesis and the precise identity of the critical carcino-
genic components in ambient air and diesel particulate matter (PM) 
are still unclear. To evaluate the health risks posed by these complex 
mixtures, understanding their mode(s) of action is crucial for accur-
ate risk assessment. It is only modes and mechanisms that can assign 
causation of speci"c events to disease along an adverse outcome 
pathway from chemical exposure. Toxic chemicals absorbed to PM 
include polycyclic aromatic hydrocarbons (PAHs) as well as nitrated 
PAHs (nitro-PAHs), which require intracellular metabolic activation 
in order to exert their carcinogenic properties through binding to 
DNA and induction of mutations (3–7).
One of the nitro-PAHs present in diesel exhaust is the nitro-
ketone 3-nitrobenzanthrone (3-NBA, 3-nitro-7H-benz[de]anthra-
cen-7-one; Figure 1) (8). 3-NBA exhibits extremely high mutagenic 
activity in vitro and produces lung tumours in rats after intratracheal 
instillation (9). It has been classi"ed as a possible human carcinogen 
(Group  2B) by IARC (1). The metabolic activation of 3-NBA to 
N-hydroxy-3-aminobenzanthrone (N-OH-3-ABA; Figure  1) is pri-
marily catalysed by NAD(P)H:quinone oxidoreductase 1 (NQO1), 
which leads to the formation of reactive nitrenium/carbenium 
ions capable of reacting with DNA (10,11). N-OH-3-ABA can be 
further activated by acetylation or sulphation catalysed by N,O-
acetyltransferases (NATs) and sulphotransferases (SULTs) form-
ing highly reactive N-acetoxy- or N-sulphoxy esters (10,12–14). 
The main reductase metabolite of 3-NBA, 3-aminobenzanthrone 
(3-ABA; Figure 1) (15–17), has been identi"ed in the urine of work-
ers occupationally exposed to diesel exhaust (18). N-oxidation 
of 3-ABA catalysed by cytochrome P450 (CYP) enzymes (e.g. 
CYP1A1) also leads to the formation of N-OH-3-ABA (19,20). The 
major DNA adducts formed by 3-NBA both in vitro and in vivo 
after its metabolic activation by reduction of the nitro group are 
2-(2ʹ-deoxyguanosin-8-yl)-3-aminobenzanthrone (dG-N2-3-ABA) 
and N-(2ʹ-deoxyguanosin-8-yl)-3-aminobenzanthrone (dG-C8-N-3-
ABA) (21,22).
The TP53 tumour suppressor gene, which encodes the protein 
p53, is one of the most important cancer genes (23–27). In response 
to cellular stress induced by various types of DNA damage, p53 
maintains genomic integrity by delaying DNA synthesis or cell div-
ision to allow DNA repair, or inducing apoptosis (28). Disruption 
of the normal p53 response by TP53 mutation leads to an increased 
risk of tumour development. TP53 is mutated in over 50% of human 
Figure 1. Possible impact of p53 on the major pathways of metabolic activation and DNA adduct formation of 3-NBA and 3-ABA. See text for details. Ac, –COCH
3
.
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tumours and various environmental carcinogens have been associ-
ated with characteristic mutational signatures in TP53 (26,27). In 
addition to its role in the DNA damage response, p53 has also been 
found to regulate metabolic pathways such as glycolysis and oxida-
tive phosphorylation thereby linking p53 not only to cancer but also 
to other diseases such as diabetes and obesity, and to other physio-
logical processes such as ageing (29).
It has been observed that abrogation of p53 activity by knockout 
or knockdown of TP53 in human cells affects carcinogen activa-
tion in vitro (23,30,31). We found that DNA adduct formation by 
the PAH benzo[a]pyrene (BaP) was signi"cantly diminished in cells 
with altered cellular p53 function and that the observed DNA dam-
age correlated with CYP1A1 expression (23). Results indicated that 
BaP-induced CYP1A1 expression is regulated through p53 bind-
ing to a p53 response element in the regulatory region of CYP1A1, 
thereby enhancing its transcription (23). Similarly, a role for p53 in 
the CYP1A1-mediated metabolism of BaP was found in vivo in mice, 
although the mechanism involved in the expression of CYP1A1 is 
different as lack of p53 function enhances BaP-DNA adduct for-
mation in vivo (24). These studies reveal a new function of p53 in 
xenobiotic metabolism.
To evaluate the impact of the cellular TP53 status on the meta-
bolic activation of 3-NBA and its reduction metabolites N-OH-3-
ABA and 3-ABA (Figure 1), we used a panel of isogenic human cell 
lines with differing TP53 status, expressing either wild-type (WT) 
p53 [TP53(+/+)], heterozygous p53 [TP53(+/−)] or mutant p53 
[TP53(R248W/+) or TP53(R248W/−)], or having a complete knock-
out of p53 [TP53(−/−)] (32). DNA adduct formation was determined 
by 32P-postlabelling. Expression of xenobiotic-metabolising enzymes 
(XMEs) involved in 3-NBA and 3-ABA metabolism was analysed by 
western blotting and quantitative reverse transcription polymerase 
chain reaction (RT-qPCR).
Materials and Methods
Carcinogens
As described previously, 3-NBA (CAS number 17117-34-9) (12) and 
3-ABA (13) were prepared. The authenticity of 3-NBA and 3-ABA 
was con"rmed by ultraviolet–visible spectroscopy, electrospray mass 
spectrometry and high-"eld proton nuclear magnetic resonance 
spectroscopy. N-OH-3-ABA was prepared as reported (20).
Cell culture and chemical treatment
Through targeted homologous recombination, a panel of isogenic 
HCT116 human colorectal carcinoma cell lines has been devel-
oped that differ only with respect to their endogenous TP53 sta-
tus. TP53(+/+), TP53(+/−), TP53(R248W/+), TP53(R248W/−) and 
TP53(−/−) cells (32) were kindly provided by Prof. Bert Vogelstein, 
Johns Hopkins University School of Medicine, Baltimore, MD. The 
R248W mutation is found in some patients with Li-Fraumeni syn-
drome and leads to substitution of arginine for tryptophan, which 
results in modulated DNA binding capacity of the corresponding 
p53 protein product.
HCT116 cells were grown as adherent monolayers in complete 
growth medium: Dulbecco’s modi"ed Eagle’s medium (#21885-025, 
Invitrogen) with 10% foetal bovine serum (#10106, Invitrogen), 
supplemented with 100 units penicillin and 100  µg streptomycin 
per millilitre. Cells were cultured at 37°C in 5% CO
2
 and passaged 
before the cells surpassed 80% con*uence. For treatment, cells were 
seeded at 3 × 104 cells/cm2, grown for 48 h and subsequently exposed 
for up to 48 h to a range of concentrations (0.5‒10 µM) of 3-NBA, 
3-ABA and N-OH-3-ABA in order to "nd the optimal conditions for 
subsequent experiments, or solvent dimethyl sulphoxide (DMSO) as 
a control. The DMSO concentration was always kept at ≤0.5% of 
the total culture medium volume. Cells were harvested by trypsinisa-
tion and washed with phosphate-buffered saline (PBS).
Cell viability by crystal violet staining
Cell viability after treatment with 3-NBA, 3-ABA and N-OH-3-
ABA was investigated using a crystal violet staining assay. Brie*y, 
the crystal violet (4-[(4-dimethylaminophenyl)-phenyl-methyl]-
N,N-dimethylaniline) method is a colorimetric assay for measuring 
adherent cells, and staining of cells occurs through binding of the 
dye to DNA. Cells were seeded on 96-well plates, grown for 48 h 
and treated with various concentrations of the test compounds or 
DMSO as control as described earlier. At least six wells were used for 
testing each concentration. After treatment, the culture medium was 
removed, plates were washed gently with PBS before cells were "xed 
and stained with a 0.1% (w/v) crystal violet solution in 10% ethanol 
for 15 min. After staining, the extracellular dye was removed by rins-
ing the wells with PBS twice. Plates were dried before crystal violet 
was solubilised again in 50% ethanol, and a plate reader (Synergy 
HT; Biotek, UK) was used to record absorbance at 595 nm. Readings 
of DMSO-exposed cells were set to represent 100% viability, and 
results for each test compound were expressed as percentage of these 
controls. Experiments were performed in triplicate.
DNA adduct analysis by 32P-postlabelling
Cells were seeded in 75-cm2 *asks and treated with the test com-
pound or DMSO as control for up to 48 h as described earlier. DNA 
was isolated from cells using a standard phenol/chloroform extrac-
tion method. The butanol extraction enrichment version of the thin-
layer chromatography (TLC) 32P-postlabelling assay was used to 
measure DNA adduct formation (33). The procedure was essentially 
as described previously (12) with minor modi"cations. Brie*y, DNA 
samples (4 µg) were digested with micrococcal nuclease (288 mU: 
Sigma) and calf spleen phosphodiesterase (1.2 mU; MP Biomedical) 
and then enriched and labelled with 50  µCi γ-32P-ATP (Hartman 
Analytic, Germany) as reported. Solvent conditions for the separ-
ation of DNA adducts were as follows: D1, 1.0 M sodium phos-
phate, pH 6.0; D3, 4 M lithium formate, 7 M urea, pH 3.5; and D4, 
0.8 M LiCl, 0.5 M Tris, 8.5 M urea, pH 8.0. After chromatography, 
TLC sheets were scanned using a Packard Instant Imager (Dowers 
Grove, IL, USA) and DNA adduct levels [relative adduct labelling 
(RAL)] were calculated from the adduct cpm, the speci"c activity of 
[γ-32P]ATP and the amount of DNA (pmol of DNA-P) used.
Western blot analysis
Cells were seeded in 25-cm2 *asks and treated with the test com-
pound or DMSO as control for 48 h as described earlier. Whole cell 
lysates were prepared as reported previously (23). Equal amounts 
of protein (10–20 µg) were separated by sodium dodecyl sulphate–
polyacrylamide gel electrophoresis using 4–12% Bis-Tris gradient 
and western blotted as previously reported (34). After blocking in 
3% nonfat milk (dissolved in PBS with 0.2% Tween-20), blots were 
incubated overnight (over 2 nights for CYP1A1) at 4°C with primary 
antibodies or antiserum diluted in blocking solution. The following 
primary antibodies and dilutions were used: anti-p53 1:2000 (Ab-6, 
Calbiochem), anti-p21 (CDKN1A) 1:2000 (556431, BD Pharmingen) 
and 1:10 000 anti-NQO1 (ab34173, Abcam). Anti-CYP1A1 raised 
in rabbits against puri"ed human recombinant CYP1A1 was a gen-
erous gift from Prof. F.  Peter Guengerich (Vanderbilt University, 
Impact of p53 function on metabolic activation of carcinogenic air pollutants, 2018, Vol. 33, No. 4 313
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USA) and was diluted 1:4000. Anti-SULT1A1/3 and anti-NAT1/2 
were kindly provided by Prof. Hansruedi Glatt (German Institute 
of Human Nutrition, Nuthetal, Germany) and used at dilutions of 
1:5000 and 1;10 000, respectively. These antisera were raised in rab-
bits against bacterial inclusion bodies of human SULT1A or NAT2 
(35,36) and were shown to exhibit some cross-reactivity detecting 
human SULT1A1 and SULT1A3, or NAT1 and NAT2 (37). The anti-
body to detect GAPDH 1:25 000 (MAB374, Chemicon) was used 
as loading control. The secondary horseradish peroxidase-linked 
antibodies were anti-mouse (170–5047; 1:10 000)and anti-rabbit 
(170–5046; 1:10 000)  from Bio-Rad. Visualisation of bands was 
accomplished using the enhanced chemiluminescent SuperSignal 
West Pico detection reagent according to the manufacturer’s instruc-
tions (Pierce, USA) and exposing the membranes to "lm. Incubations 
were carried out at least in duplicate.
Gene expression analysis
Cells were seeded in 25-cm2 *asks and treated with the test com-
pound or DMSO as control for 24 h as described earlier. RNA was 
isolated and reverse transcribed into cDNA as reported previously 
(23). Relative quantitation of NQO1 and CYP1A1 mRNA expres-
sion was performed using *uorescent RT-qPCR with the ABI PRISM 
7500HT Fast Sequence Detection System (Applied Biosystems, UK) 
(23). NQO1 and CYP1A1 expression was detected using TaqMan® 
gene expression primers and probes (NQO1-Hs02512143_s1 and 
CYP1A1-Hs00153120_m1) with GAPDH as endogenous control 
(GAPDH-Hs02758991_g1). Relative gene expression was calcu-
lated using the comparative threshold cycle (C
T
) method.
Results
Cell viability after exposure to 3-NBA and its 
metabolites
At "rst, the effect of the test compounds on the viability of HCT116 
TP53(+/+) cells was analysed by crystal violet staining to guide 
concentrations to be tested for each compound in further experi-
ments in comparison with cells having altered TP53 expression. 
HCT116 TP53(+/+) cells were subjected to treatment with 0.5, 1, 
5 and 10 µM of 3-NBA, 3-ABA or N-OH-3-ABA, or with solvent 
DMSO only (control) for 24 and 48 h (Figure 2). After exposure 
to 3-NBA, TP53(+/+) cells exhibited a concentration-dependent 
decrease in cell viability, which was far more pronounced after 48 h 
compared to 24  h exposure. At the highest 3-NBA concentration 
(10 µM), viability decreased to ฏ50% after 24 h and to ฏ25% after 
48 h in comparison to controls (Figure 2A). Treatment with 3-ABA 
and N-OH-3-ABA did not show any signi"cant effect on cell via-
bility at the used concentrations and time points (Figure 2B and C).
DNA adduct formation after exposure to 3-NBA and 
its metabolites
To determine nitro/amino-PAH-derived DNA adduct formation, 
HCT116 TP53(+/+), TP53(+/−), TP53(−/−), TP53(R248W/+) and 
TP53(R248W/−) cells were exposed to 1 µM 3-NBA, 10 µM 3-ABA 
or 1 µM N-OH-3-ABA for 24 and 48 h and their DNA was ana-
lysed by the 32P-postlabelling method (Figure 3). The test concen-
trations were selected based on the cell viability data obtained in 
HCT116 TP53(+/+) (see Figure 2). For 3-NBA and N-OH-3-ABA, 
treatment conditions were in accordance with a previous study using 
HCT116 TP53(+/+) cells (38); 3-ABA had not been tested previ-
ously. Treatment with 3-NBA, 3-ABA and N-OH-3-ABA resulted in 
the formation of the same four major adduct spots in all cell lines 
(see inserts to Figure 3), which corresponded to adducts formed in 
vivo (15,21,22,38). Three of these adducts were previously identi-
"ed as 2-(2ʹ-deoxyadenosin-N6-yl)-3-aminobenzanthrone (dA-N6-
3-ABA, spot 1), N-(2ʹ-deoxyguanosin-N2-yl)-3-aminobenzanthrone 
(dG-N2-3-ABA, spot 3)  and N-(2ʹ-deoxyguanosin-8-yl)-3-
aminobenzanthrone (dG-C8-N-3-ABA, spot 4)  (21). The adduct 
formed at spot 2 has not been identi"ed fully yet but is categorised 
as a dA adduct (22).
Of the three compounds, 3-NBA gave rise to the highest total 
levels of DNA adducts (up to ฏ1500 adducts per 108 nucleotides). 
Used at 1  µM, 3-NBA-induced DNA adduct levels were ~10-fold 
higher than N-OH-3-ABA (1 µM) and ~100-fold higher than 3-ABA 
Figure  2. Effect of 3-NBA, 3-ABA and N-OH-3-ABA on cell viability in 
HCT116 TP53(+/+) cells. Cells were exposed to 0.5, 1, 5 and 10 µM of the test 
compounds for 24 h (black line) or 48 h (grey line). Values are means ± SD of 
two separate incubations with two biological samples each (n = 4).
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(10 µM). DNA adduct levels resulting from 3-NBA treatment were 
similar in all cell lines except for TP53(R248W/−) cells, which showed 
signi"cantly higher adduct levels at both time points. 3-NBA-derived 
DNA adduct levels decreased slightly from 24 to 48 h (Figure 3A), 
which may be linked to increased cytotoxicity at 48 h.
Similar adduct levels were observed in TP53(+/+), TP53(R248W/+) 
and TP53(R248W/−) cells after treatment with 3-ABA and they 
increased from 24 to 48  h [TP53(+/+): ~2-fold; TP53(R248W/+): 
~1.3-fold; TP53(R248W/−): ~1.3-fold]. Compared with TP53(+/+) 
cells, adduct levels were signi"cantly lower (~8-fold at 24 h and ~14-
fold at 48 h) in TP53(+/−) and TP53(−/−) cells (Figure 3B).
After treatment with N-OH-3-ABA, TP53(+/+) and 
TP53(R248W/+) cells formed similar amounts of DNA adducts at 
both time points (Figure  3C). TP53(R248W/−) cells also formed 
similar adduct levels 48  h after treatment but signi"cantly higher 
DNA adducts were detected at 24 h for this cell line. As seen for 
3-ABA, DNA adduct levels were signi"cantly lower in TP53(+/−) and 
TP53(−/−) cells compared to TP53(+/+) cells [i.e. TP53(+/−): 4-fold 
at 24 h and 6-fold at 48 h; TP53(−/−): 5-fold at 24 h, 6-fold at 48 
h]. Generally, N-OH-3-ABA-derived DNA adduct levels decreased 
slightly from 24 to 48 h.
Expression of DNA damage response proteins after 
exposure to 3-NBA and its metabolites
HCT116 TP53(+/+), TP53(+/−), TP53(−/−), TP53(R248W/+) and 
TP53(R248W/−) cells were treated with 1  µM 3-NBA, 10  µM 
3-ABA, 1 µM N-OH-3-ABA or DMSO alone (control) for 48 h and 
whole cell lysates were analysed for the expression of p53 and p21 
by western blotting. Both proteins have been shown to be sensitive 
markers to assess DNA damage response in HCT116 cells (23,39). 
As seen in Figure 4, treatment with 3-NBA resulted in strong induc-
tion of p53 in TP53(+/+), TP53(R248W/+) and TP53(R248W/−) 
cells whereas 3-ABA and N-OH-3-ABA induced p53 to a lesser 
Figure 3. DNA adduct levels in isogenic HCT116 cells exposed to 3-NBA (A), 3-ABA (B) and N-OH-3-ABA (C) for 24 or 48 h. Cells were treated with 1 µM 3-NBA, 10 µM 
3-ABA and 1 µM N-OH-3-ABA and analysed by 32P-postlabelling. Values are means ± SD of two separate incubations with two independent samples each (n = 4). 
Statistical analysis was performed by one-way ANOVA followed by the Tukey post hoc test [***P < 0.001; different from HCT116 TP53(+/+) cells]. Insets: Representative 
autoradiographic proﬁles of DNA adducts formed in HCT116 cells after exposure; the origins, at the bottom left-hand corners, were cut off before imaging.
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extent in these cell lines. In TP53(+/−) cells, basal levels and induc-
tion of p53 were strongly decreased and no p53 was detectable in 
TP53(−/−) cells. Induction of p21 was strongest after treatment with 
3-NBA whereas 3-ABA and N-OH-3-ABA led to only moderate 
changes compared with controls. Induced and basal p21 expression 
was highest in TP53(+/+), followed by TP53(+/−) and TP53(R248/+) 
cells and greatly decreased in TP53(−/−) and TP53(R248/−) cells.
Expression of XMEs after exposure to 3-NBA and its 
metabolites
It has been shown that 3-NBA is predominantly activated by NQO1 
(10,11). Using Western blotting, we determined NQO1 protein 
expression in whole cell lysates isolated from HCT116 TP53(+/+), 
TP53(+/−), TP53(−/−), TP53(R248W/+) and TP53(R248W/−) cells 
treated with 1 µM 3-NBA, 10 µM 3-ABA, 1 µM N-OH-3-ABA or 
DMSO alone (control) for 48  h (Figure  4). Expression of NQO1 
protein was treatment independent and similar in all cell lines. 
These "ndings were in line with the RT-qPCR data in HCT116 
cells exposed under the same experimental conditions for 24 h; no 
signi"cant differences in NQO1 gene expression were detectable 
between the cell lines after exposure to any of the three compounds 
(Figure 5A–C).
3-ABA is activated by CYP1A1 (16). Two bands were detected 
on the western blot for CYP1A1; the top band is the correct molecu-
lar weight (58 kDa). In addition, previous experiments have shown 
that the top band increases with higher BaP concentrations used 
and also that it diminishes when BaP-treated cells have been trans-
fected with CYP1A1 siRNA (Kucab and Arlt, unpublished data). 
Thus, the lower band is assumed to be nonspeci"c. The antibody has 
been shown to be sensitive to detect human CYP1A1 protein in cul-
tured human cells (including HCT116) exposed to BaP (23,39–41). 
However, in this study CYP1A1 protein expression after 3-NBA, 
3-ABA and N-OH-ABA exposure was weak or hardly detectable 
(Figure 4). These "ndings could indicate that 3-NBA, 3-ABA and 
N-OH-ABA, in contrast to BaP, do not or only weakly induce 
CYP1A1 expression in HCT116 cells. However, they may also 
be due to the insensitivity of the antibody to detect low amounts 
of CYP1A1 protein in whole cell lysates. As CYP1A1 protein 
expression in HCT116 cells after 3-NBA, 3-ABA and N-OH-ABA 
exposure was low and close to background, no solid conclusions 
could be drawn on the impact of p53 function. As a more sensi-
tive measure, we therefore measured and quanti"ed CYP1A1 gene 
expression by RT-qPCR (Figure 5D–F). For 3-NBA treatment, the 
increase in CYP1A1 expression was signi"cantly higher (~2-fold) in 
TP53(R248W/+) and TP53(R248W/−) cells compared with the other 
cell lines (Figure 5D). It is noteworthy that in TP53(R248W/−) cells 
increased CYP1A1 expression correlated with higher DNA adduct 
levels (see Figure  3A). In TP53(+/+), TP53(+/−) and TP53(−/−) 
cells, 3-NBA treatment induced CYP1A1 to a similar extent, which 
correlated with similar adduct levels. These results suggest that 
mutant-R248W-p53 but not WT-p53 impacts on 3-NBA-mediated 
CYP1A1 induction. In contrast, exposure to 3-ABA and N-OH-3-
ABA led to signi"cantly higher CYP1A1 mRNA levels in TP53(+/+) 
cells compared to the other cell lines, pointing towards a WT-p53-
dependent impact on the CYP1A1-mediated bioactivation of these 
compounds. Overall, CYP1A1 expression was altered to a greater 
extent than NQO1, suggesting a greater role of the former in modu-
lating the metabolism of these compounds in these cells.
N-OH-3-ABA can be further activated by SULTs, particularly 
SULT1A1 (10,12,13). The SULT1A antiserum used is able to detect 
SULT1A1 and SULT1A3 protein (37). As both SULT1A enzymes 
show cross-reactivity and the same electrophoretic mobility expres-
sion, they were analysed as a group rather than as individual proteins. 
SULT1A1/3 protein expression was not affected by treatment with 
any of the compounds, but basal levels were highest in TP53(+/+), 
TP53(R248W/+) and TP53(R248W/−) cells and were substantially 
lower in TP53(−/−) and TP53(+/−) cells (Figure 4).
NAT1 and NAT2 have also been shown to enhance the genotox-
icity of both 3-NBA and 3-ABA (10,12,13). The NAT1/2 antiserum 
used has previously shown cross-reactivity towards NAT1 and 
NAT2 (37) and expression of both was analysed as a group because 
separation of the two bands proved dif"cult (Figure 4). Expression 
of NAT1/2 protein was treatment independent and similar in all 
cell lines.
Figure 4. Western blot analysis of p53, p21 (CDKN1A), NQO1, CYP1A1, NAT1/2 
and SULT1A1/3 protein expression in isogenic HCT116 cells after exposure to 
3-NBA (A), 3-ABA (B) and N-OH-3-ABA (C) for 48 h. Cells were treated with 1 µM 
3-NBA, 10 µM 3-ABA and 1 µM N-OH-3-ABA. GAPDH protein expression was used 
as a loading control. Representative images of the Western blotting are shown; at 
least duplicate analysis was performed from independent experiments.
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Discussion
Our study aimed to evaluate the impact of p53 function on the 
metabolic activation of the carcinogenic air pollutant 3-NBA and 
its reduction metabolites N-OH-3-ABA and 3-ABA. Because no 
human lung cell lines with disrupted TP53 were available, we used 
isogenic human colorectal HCT116 differing only with respect 
to their TP53 status; these cells were created by targeted hom-
ologous recombination. They have been proven to be a valuable 
tool to investigate cellular responses associated with the TP53 
network including carcinogen metabolism (23,30,31,39,42–44). 
In addition, previous studies have used human HCT116 cells 
to investigate the genotoxicity of 3-NBA and/or N-OH-3-ABA 
(30,31,38).
Similar 3-NBA-derived DNA adduct levels in the HCT116 
TP53(+/+), TP53(+/−) and TP53(−/−) cell lines suggest a WT-TP53-
independent metabolic activation of this compound. These adduct 
results for 3-NBA in the TP53(+/+) and TP53(−/−) cell lines are in 
line with earlier "ndings (30,31) when tested at a higher concentra-
tion (i.e. 5 µM). Because bioactivation of 3-NBA by simple nitrore-
duction is primarily catalysed by NQO1, rather than CYP enzymes 
(8,11,45), these results indicate that NQO1 expression is not in*u-
enced by TP53 status. This corresponds with the observation that 
no impact of WT-p53 status was seen on the induction of NQO1 at 
either the protein or mRNA level. Similarly WT-p53 status had no 
effect on CYP1A1 mRNA expression.
Nucleotide excision repair (NER) is the main DNA repair path-
way for many bulky DNA adducts such as those derived from PAHs 
such as BaP, and p53-dependent pathways affecting global NER 
have been identi"ed (26). Using a modi"ed comet assay, we pre-
viously phenotypically assessed the NER capacity of the different 
HCT116 cells and found that all HCT116 cell lines used had the 
same NER capacity (23). Other studies have suggested that 3-NBA-
DNA adducts may not be recognised by NER, explaining the high 
mutagenic potency of 3-NBA (27). Collectively these "ndings indi-
cate that differences in DNA adduct formation in HCT116 cell lines 
exposed to 3-NBA and its metabolites are solely related to differ-
ences in their bioactivation and not to p53-dependent differences in 
DNA repair.
DNA adduct levels formed after incubations with the metabolite 
3-ABA were signi"cantly lower in TP53(+/−) and TP53(−/−) cell lines 
compared with TP53(+/+) cells. As bioactivation (i.e. N-oxidation) 
of 3-ABA to N-OH-3-ABA is catalysed by CYP1A1 (15,16,46,47), 
these results can be explained by diminished induction of CYP1A1 
mRNA in these cell lines compared with TP53(+/+) cells (Figure 1). 
Previous studies have also shown that 3-ABA is able of inducing 
CYP1A1 expression, thereby enhancing its own metabolic activation 
(48,49). Taking the results of this study into account, these "ndings 
indicate an in*uence of WT-p53 on the CYP1A1-mediated bioacti-
vation of 3-ABA.
Both 3-NBA and 3-ABA share the same intermediate N-OH-
3-ABA, which is capable of reacting with DNA to form adducts 
(20,38). The genotoxicity of N-OH-3-ABA can be enhanced by 
SULTs or NATs, leading to reactive N-acetoxy or N-sulphoxy esters 
(10,12,14,19). N-OH-3-ABA-induced DNA adducts were lower in 
TP53(+/−) and TP53(−/−) cells than in TP53(+/+) cells, which cor-
responded with lower SULT1A1/3 protein expression in TP53(+/−) 
Figure 5. Change in gene expression of NQO1 (upper panels) and CYP1A1 (lower panels) in isogenic HCT116 cells after exposure to 3-NBA, 3-ABA and N-OH-3-
ABA. Cells were exposed to 1 µM 3-NBA (A + D), 10 µM 3-ABA (B + E) and 1 µM N-OH-3-ABA (C + F) for 24 h. In addition, control samples for each cell line were 
treated with DMSO before total RNA was extracted, and the mRNA levels of the indicated genes were analysed by qRT-PCR. Values are means ± SD of three 
incubations; each sample was determined by three separate analyses. Each bar represents the fold change in expression caused by exposure to the respective 
compound (3-NBA, 3-ABA or N-OH-3-ABA) of each cell line and was calculated using the formula 2−∆∆CT. Statistical analysis was performed by one-way ANOVA 
followed by the Tukey post hoc test [**P < 0.01, ***P < 0.001; different from HCT116 TP53(+/+) cells].
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and TP53(−/−) cells, whereas NAT1/2 protein expression was similar 
in all cell lines. These results suggest that the SULT-mediated bioacti-
vation of N-OH-3-ABA seems to be dependent on WT-p53.
As N-OH-3-ABA is a metabolite of both 3-NBA and 3-ABA, the 
impact of WT-p53 on SULT expression in*uencing DNA binding 
by N-OH-3-ABA might also contribute to 3-NBA- or 3-ABA-DNA 
adduct formation. However, DNA adduct formation by 3-NBA was 
not signi"cantly different in TP53(+/−), TP53(−/−) and TP53(+/+) 
cells suggesting that in HCT116 cells the rate-limiting step of the 
bioactivation pathway of 3-NBA is the conversion of 3-NBA to 
N-OH-3-ABA. In contrast, because p53 impacts on the expression of 
both SULT1A1/3 and CYP1A1 after 3-ABA incubation, it is not clear 
which is the rate-limiting step in the metabolic activation of 3-ABA.
It has been shown that partial inactivation of tumour suppressor 
genes such as TP53 can contribute to carcinogenesis, suggesting that 
one copy of TP53 is not suf"cient to maintain a functional WT con-
dition (haploinsuf"ciency). Loss of a single copy of TP53 can give 
rise to a phenotype intermediate to that occurring after complete 
loss of the gene (50,51). Therefore, it could have been expected that 
HCT116 TP53(+/−) cells would generate an intermediate response 
to those observed in TP53(−/−) and TP53(+/+) cells. However, 
the results obtained for 3-ABA and N-OH-3-ABA suggest that in 
HCT116 TP53(+/−) cells, the remaining WT allele is not suf"cient 
for normal cellular function, which was also indicated in another 
study using these cells (52). Similar results have been observed in 
HCT116 TP53(+/−) cells treated with PAHs such as BaP, dibenz[a,h]
anthracene and dibenzo[a,l]pyrene (23). An explanation could be 
that transcriptional activation by p53 is dependent on its tetrameric 
structure and that the 50% reduction in protein dosage results in a 
disproportionate reduction in active tetramer concentrations (53).
More than 50% of human tumours carry a mutation in TP53 
and some mutation patterns and spectra in TP53 in human tumours 
have been linked to speci"c environmental exposures (26,28). It has 
also been shown that 3-NBA induces characteristic mutations in 
TP53 using the human TP53 knock-in (Hupki) mouse model (27). 
Mutations in TP53 can not only abrogate the tumour suppressor 
functions of WT-p53 (loss-of-function mutation) but can also equip 
the mutant protein with new activities (gain-of-function mutation), 
which can contribute to various stages of tumour progression (54). 
As shown in the IARC TP53 Database (http://p53.iarc.fr; version 
R18), codon 248 is the most frequently mutated codon in TP53 in 
human tumours. The exchange of a native arginine for tryptophan 
in p53’s DNA-binding region (R248W) induces conformational 
changes and has been shown to abolish the tumour suppressive 
activity of p53 (55). Thus, studying the response of cells with this 
mutation (R248W) in TP53 to environmental carcinogens can give 
insights into how mutations contribute to carcinogenesis.
3-ABA-DNA adduct levels in both cell lines that carried mutated 
p53 were similar to that in TP53(+/+) cells. Whereas the higher lev-
els of 3-ABA-DNA adducts in TP53(+/+) compared with TP53(+/−) 
and TP53(−/−) cells could be explained by higher CYP1A1 expres-
sion in the former, this could not be seen for TP53(R248W/+) or 
TP53(R248W/−). Rather they could be interpreted as the result of 
higher SULT1A1/3 expression in these cell lines.
It has been shown that under anaerobic conditions, CYP1A1 
is also capable of catalysing the nitroreduction of 3-NBA (19,56) 
although this reaction is otherwise primarily catalysed by NQO1 
(11). In TP53(R248W/−) cells, signi"cantly higher 3-NBA-DNA 
adducts corresponded with a signi"cantly greater induction of 
CYP1A1, but although CYP1A1 was induced to a similar extent 
in TP53(R248W/+) cells, it did not result in the same amount of 
3-NBA-DNA adducts. It can be speculated that CYP1A1 expression 
impacts on 3-NBA-DNA adduct formation in these cells. However, 
why the signi"cant difference in CYP1A1 expression in both cell 
lines that have mutant p53 results in signi"cantly higher adduct 
levels only in TP53(R248W/−) cells and not in TP53(R248W/+) 
cells remains unclear. Similarly, as SULT1A1/3 and NAT1/2 expres-
sion was equally high in TP53(R248W/−), TP53(R248W/+) and 
TP53(+/+) cells, the contrasting 3-NBA-DNA adduct levels in 
TP53(R248W/−) cells seem not to be attributable to SULT-mediated 
bioactivation of this compound. These "ndings indicate that the 
in*uence of mutated p53 on the regulation of XMEs might be more 
complex. Furthermore, they also suggest that studying the impact of 
p53, whether WT or mutated, on carcinogen metabolism is a chal-
lenge if p53 function impacts on multiple XMEs.
The same phenomenon was observed after treatment with N-OH-
3-ABA. Although TP53(+/+), TP53(R248W/+) and TP53(R248W/−) 
cells displayed similar SULT1A1/3 and NAT1/2 protein expres-
sion, N-OH-3-ABA-DNA adduct levels were signi"cantly higher in 
TP53(R248W/−) cells, showing that the mutant-p53 mechanism of 
action differs from that of WT-p53. Thus, these "ndings demonstrate 
a gain-of-function for the mutated R248W-p53 protein. Similarly, 
acquisition of new functions for this mutant has been shown before 
in the HCT116 TP53(R248W/−) cell line (57) and in the Hupki 
mouse model (55). In this study, the acquired function might be 
exerted through activation of other XMEs.
Another enzyme that has been shown to activate both 3-NBA and 
3-ABA is CYP1A2 (56,58). Although CYP1A2 expression was not 
determined in this study, it is known to be restricted predominantly to 
the liver (59), thus its contribution to the bioactivation of 3-NBA and, 
particularly, of 3-ABA in the colorectal HCT116 cells used here would 
be expected to be negligible. It is noteworthy that treatment of HCT116 
TP53(+/+) cells with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyri-
dine (PhIP), which is mainly activated by CYP1A2, did not lead to 
detectable DNA adduct formation even at high concentrations of up 
to 200 µM (Wohak et al., unpublished data). Conversely, p53-depend-
ent PhIP-DNA adduct formation has been demonstrated in a Trp53 
mouse model in vivo (25). N-OH-3-ABA can also be conjugated by 
another enzyme, SULT1A2 (10,12). Tissue distribution of this SULT is 
restricted mainly to the liver and bladder (60), although low amounts 
have been detected in another human colon carcinoma cell line (Caco-
2) (61) and in some human colon samples (36). Furthermore, the 
microsomal enzyme NADPH:P450 oxidoreductase (POR), which is 
the electron donor of CYP enzymes (62), is also capable of activating 
3-NBA through simple nitroreduction in cell-free experimental systems 
(56). However, using the Hepatic Reductase Null mouse model, in 
which POR is speci"cally deleted in hepatocytes, it was shown that bio-
activation of 3-NBA is dependent predominantly on cytosolic NQO1 
rather than microsomal POR (10). Although the activation pathways 
of 3-NBA and its metabolites have been well studied (8,19), knowledge 
of the enzymes detoxifying 3-NBA is sparse. Thus it is possible that 
other XMEs that have not yet been investigated might in*uence the 
results obtained in the HCT116 model.
In both cases where a signi"cant impact of the mutant p53 on 
adduct formation (3-NBA- and N-OH-3-ABA-derived adducts) was 
found in TP53(R248W/−) cells, TP53(R248W/+) cells generated 
DNA adduct levels intermediate between the TP53(R248W/−) and 
TP53(+/+) cell lines. This might indicate that this altered function 
of the R248W-p53 may be compensated for by a WT-p53 in the 
TP53(R248W/+) cell line.
Although there are previous reports that NATs, especially NAT2, 
may be more important than SULTs in the bioactivation of 3-NBA 
(8,10,11), this study indicates that in HCT116 cell lines, the SULTs 
seem to have a greater impact.
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Our past studies (23–25,30,31,39), the present one and those of 
others (63–66), also demonstrate that p53’s in*uence depends on 
the class of xenobiotic compound and thereby on the XMEs that 
mediate the bioactivation of the particular compounds. To form con-
clusions for the whole class of nitro-PAHs, this study will have to 
be widened to include other nitro-PAHs. Another nitroaromatic car-
cinogen that has been tested in HCT116 TP53(+/+) and TP53(−/−) 
cells is aristolochic acid I  (AAI) (31), a potent human carcinogen 
linked to urothelial cancer (67,68). AAI is primarily activated by 
NQO1-catalysed nitroreduction, whereas CYP1A-mediated demeth-
ylation contributes to AAI detoxi"cation (69). Previous studies have 
shown that AAI–DNA adduct formation was signi"cantly higher in 
TP53(+/+) relative to TP53(−/−) cells and cellular TP53 status may 
impact on CYP1A1-mediated AAI bioactivation (31,70).
Conclusions
This study illustrates the impact of p53 function on the metabolic 
activation of 3-NBA and its metabolites 3-ABA and N-OH-3-ABA. 
Although WT-p53 had no in*uence on 3-NBA-derived DNA adduct 
formation, lower 3-ABA- and N-OH-ABA-derived DNA adducts 
levels in TP53(+/−) and TP53(−/−) cells than in TP53(+/+) cells 
corresponded with diminished expression of CYP1A1 mRNA and 
SULT1A1/3 protein in these cells. Our results show that p53’s in*u-
ence on carcinogen activation depends on the class of carcinogen and 
on the XMEs that mediate the bioactivation of the particular xeno-
biotic. The in*uence of p53 on regulating CYP1A1 and SULT1A1/3 
expression is in line with other recent studies demonstrating this phe-
nomenon (23–25,39). However, this is the "rst study highlighting the 
impact of p53 on SULT-mediated carcinogen metabolism in human 
cells. Because SULTs are involved in controlling the balance of many 
endogenous molecules such as steroids, sterols, thyroid hormones and 
catecholamines (60,71), our results may also suggest a role for p53 in 
endocrine signalling pathways. Our study also showed that mutant 
R248W-p53 protein function was similar to, or even exceeded, the 
ability of WT-p53 in activating 3-NBA and its metabolites, measured 
as DNA adducts, but it is possible that cells carrying a different TP53 
mutation to R248W may respond differently. Future studies could 
aim for a more comprehensive approach to examining the impact of 
distinct TP53 mutations in isogenic cells for a comparative functional 
analysis of mutant p53 and carcinogen metabolism.
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